Patents by Inventor Gregory Burshtein
Gregory Burshtein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200138913Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.Type: ApplicationFiled: December 23, 2019Publication date: May 7, 2020Applicant: Entera Bio Ltd.Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Patent number: 10583177Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.Type: GrantFiled: February 9, 2016Date of Patent: March 10, 2020Assignee: Entera Bio Ltd.Inventors: Gregory Burshtein, Ariel Rothner, Phillip M. Schwartz, Hillel Galitzer
-
Publication number: 20190209657Abstract: Pharmaceutical compositions comprising a therapeutically active agent and an absorption enhancer such as NAC, NAD, 5-CNAC, 4-MOAC, 4-CNAB or a salt thereof, for use in the treatment of a condition treatable by said therapeutically active agent, are provided. The compositions are for concomitant oral administration of two or more of the unit dosage form, which form together a therapeutically effective amount of the therapeutically active agent and an effective amount of the absorption enhancer. Multi-dose compositions comprising the two or more of the unit dosage form are also provided.Type: ApplicationFiled: August 17, 2017Publication date: July 11, 2019Applicant: Entera Bio Ltd.Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20180050096Abstract: A pharmaceutical composition for use in the treatment of hypoparathyroidism by oral administration of the composition is provided herein. The composition comprises parathyroid hormone or a fragment thereof; and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate). Further disclosed are uses of the composition in the preparation of a medicament and methods of treating hypoparathyroidism utilizing the composition.Type: ApplicationFiled: February 9, 2016Publication date: February 22, 2018Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20180036234Abstract: A pharmaceutical composition for use in the treatment of a medical condition associated with a bone fracture and/or a bone defect is provided herein, wherein the treatment is effected by oral administration of the composition. The composition comprises parathyroid hormone or a fragment thereof, and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate). Further disclosed are uses of the composition in the preparation of a medicament and methods of treating a bone fracture and/or bone defect utilizing the composition.Type: ApplicationFiled: February 9, 2016Publication date: February 8, 2018Applicant: Entera Bio Ltd.Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20180036382Abstract: A pharmaceutical composition comprising a therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate) is provided herein. The composition is formulated for oral administration and is such that the SNAC is active in enhancing absorption of the therapeutically active agent for no more than 60 minutes, and/or such that absorption of the therapeutically active agent following oral administration of the composition is characterized by a ratio of AUC to Cmax which is 60 minutes or lower and/or by a Tmax which is 60 minutes or lower. Further disclosed herein are uses and methods utilizing the compositions described herein for treating a condition treatable by oral administration of a therapeutically active agent in a subject in need thereof.Type: ApplicationFiled: February 9, 2016Publication date: February 8, 2018Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20180028622Abstract: A pharmaceutical composition for use in the treatment of osteoporosis by oral administration of the composition is provided herein. The composition comprises parathyroid hormone or a fragment thereof; and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate). Further disclosed are uses of the composition in the preparation of a medicament and methods of treating osteoporosis utilizing the composition.Type: ApplicationFiled: February 9, 2016Publication date: February 1, 2018Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20180021272Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.Type: ApplicationFiled: February 9, 2016Publication date: January 25, 2018Applicant: Entera Bio Ltd.Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Philip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20130040982Abstract: Sustained-release formulations comprising huperzine A are disclosed herein. The formulations are for oral administration, and contain a carrier which comprises native albumin. Unit dosage forms of the formulations, and kits comprising such unit dosage forms are also disclosed herein. Methods utilizing the formulations for treating a medical condition treatable by huperzine A are also disclosed herein, as well as processes for preparing the formulations, and uses of huperzine A and albumin in the manufacture of a medicament.Type: ApplicationFiled: April 20, 2011Publication date: February 14, 2013Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Michael Friedman, Amnon HOffman, Gregory Burshtein